FDA Approves Stelara: New Ulcerative Colitis Treatment from J&J

The U.S. Food and Drug Administration (FDA) has granted FDA Stelara approval for ustekinumab (Stelara) for the treatment of moderate to severe Ulcerative Colitis in adult patients. This approval expands the indications for ustekinumab, a human monoclonal antibody developed by Johnson & Johnson, providing a new option for patients who have had an inadequate response or intolerance to conventional therapies. The ustekinumab approval is based on Phase 3 clinical trials, marking a significant advancement in treating this Inflammatory Bowel Disease.

Drug Overview

Ustekinumab (Stelara) is a human monoclonal antibody that targets the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23). By blocking these cytokines, ustekinumab modulates inflammatory pathways implicated in ulcerative colitis pathology. It is now approved for the treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response or intolerance to conventional therapies. Previously, ustekinumab was approved for psoriasis, psoriatic arthritis, and Crohn's disease.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for ulcerative colitis, with ustekinumab most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Clinical Insights

The FDA approval for ustekinumab in ulcerative colitis was based on pivotal Phase 3 clinical trials. [Source: U.S. Food and Drug Administration] These trials demonstrated significant improvement in clinical remission and endoscopic response at week 8 for induction and week 44 for maintenance. Common adverse events include upper respiratory infections, headache, fatigue, and injection site reactions. Serious risks include infections due to immunosuppression and potential hypersensitivity reactions. The safety profile is consistent with other approved indications.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Regulatory Context

The FDA approval for ustekinumab followed a Biologics License Application (BLA). Typical FDA approval for biologics in ulcerative colitis involves phased clinical development: Phase 1 safety, Phase 2 dose-ranging and proof-of-concept, and Phase 3 pivotal efficacy and safety trials. The BLA submission includes clinical, nonclinical, and CMC data. Safety signals associated with ustekinumab include upper respiratory infections, headache, fatigue, and injection site reactions. Serious risks include infections due to immunosuppression and potential hypersensitivity reactions.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for ulcerative colitis pricing, access, and launch sequencing.

Market Impact

Ustekinumab enters a competitive market for ulcerative colitis treatments, including TNF inhibitors such as infliximab and adalimumab, as well as other classes like vedolizumab, risankizumab, and tofacitinib. The target population includes adult patients with moderate to severe ulcerative colitis who have had an inadequate response or intolerance to conventional therapies, representing several hundred thousand patients in the US. Ustekinumab's approval provides an additional biologic treatment option, potentially capturing patients inadequately controlled by existing therapies.

IntelligenceStrategic Takeaways▾

Stelara, recently approved by the FDA, provides a new treatment option for ulcerative colitis, promising improved outcomes for patients.

Future Outlook

Future developments for ustekinumab may include exploring label expansions and combination trials. Its unique mechanism of action targeting IL-12/23 pathways may offer advantages in specific patient subsets, warranting further investigation.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-08.

IntelligenceEvidence Quality▾

Claims are grounded in the cited primary and secondary sources, with editorial review applied before publication.

Related profiles

• ustekinumab

Related coverage

• J&J reports positive Phase 3 Tremfya data in ulcerative colitis
• FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
• FDA approves Merck’s Keytruda for adjuvant NSCLC treatment